Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3Phase 3 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × chiauranib × Clear all
NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed
40 enrolled
Sarcoma

Sarcoma

NCT05336721 2025-03-24

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Chipscreen Biosciences, Ltd.

Phase 2 Terminated
9 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡